EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access

Recurrent stroke in patients with history of stroke/transient ischemic attack and device-detected atrial fibrillation: A systematic review and meta-analysis

Rezidivierender Schlaganfall bei Patient:innen mit Schlaganfall-/TIA-Anamnese und geräteerfasstem Vorhofflimmern: systematische Übersichtsarbeit und Metaanalyse

Lina Palaiodimou iD, Aristeidis H Katsanos iD, Konstantinos Melanis iD, Maria-Ioanna Stefanou, Michele Romoli iD, Georgia Papagiannopoulou, Aikaterini Theodorou, Martin Köhrmann, Polychronis Dilaveris, Konstantinos Tsioufis, Gkikas Magiorkinis, Christos Krogias und 5 weitere

European Stroke Journal · 01.12.2025 · 10 (4) · 1221-1230

DOI: 10.1177/23969873251334278 ↗

Auf einen Blick

Zwei RCTs mit 599 Patient:innen zeigen: Antikoagulation senkte rezidivierende Schlaganfälle, erhöhte aber das Risiko für schwere Blutungen.

Fragestellung

Verringert Antikoagulation bei Patient:innen mit geräteerfasstem Vorhofflimmern nach Schlaganfall oder TIA das Risiko für erneute Schlaganfälle?

Methode

Systematische Übersichtsarbeit und Metaanalyse von RCTs zu Antikoagulation bei DDAF nach Schlaganfall oder TIA.

Ergebnisse

2 RCTs mit 599 Patient:innen. Any stroke recurrence: RR 0,47 (95 %-KI 0,23–0,94; p=0,034), NNT=34. Major bleeding: RR 2,30 (95 %-KI 1,06–4,98; p=0,035), NNH=37.

Schlussfolgerung der Autor:innen

Antikoagulation senkt bei DDAF nach Schlaganfall/TIA das Risiko für erneute Schlaganfälle, erhöht aber das Risiko für schwere Blutungen.

Kernaussagen

  • Weniger erneute Schlaganfälle unter Antikoagulation
  • Mehr schwere Blutungen unter Antikoagulation
  • Keine Unterschiede bei mehreren weiteren Endpunkten

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Stroke Journal, online erschienen am 01.12.2025. Verfasst von Lina Palaiodimou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Hauptthemen laut MEDLINE: Atrial Fibrillation, Ischemic Attack, Transient, Stroke, Anticoagulants. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prolonged cardiac monitoring after stroke increases the detection of device-detected atrial fibrillation (DDAF), leading to a clinical dilemma regarding anticoagulation for secondary stroke prevention. While anticoagulation reduces thromboembolic risk in clinical AF, its benefit-risk profile in DDAF remains uncertain.

Methods

In this systematic review and meta-analysis, randomized-controlled clinical trials (RCTs) evaluating anticoagulation among patients with DDAF post stroke or transient ischemic attack (TIA) were pooled. The primary efficacy outcome was any stroke recurrence, while stroke or systemic embolism, ischemic stroke recurrence, myocardial infarction, and cardiovascular mortality were assessed as secondary efficacy outcomes. The primary safety outcome was major bleeding, while hemorrhagic stroke and all-cause mortality were assessed as secondary safety outcomes.

Results

Two RCTs with 599 patients (294 anticoagulation, 305 no-anticoagulation) were included. Anticoagulation significantly reduced any stroke recurrence (RR: 0.47; 95% CI: 0.23–0.94; p = 0.034; number-needed-to-treat = 34). Anticoagulation lowered the risk of the composite outcome of stroke recurrence and systemic embolism (RR: 0.45; 95% CI: 0.22–0.90; p = 0.023). However, anticoagulation was associated with an increased risk of major bleeding (RR: 2.30; 95% CI: 1.06–4.98; p = 0.035; number-needed-to-harm = 37). There were no differences in ischemic stroke recurrence (RR: 0.53; 95% CI: 0.26–1.09; p = 0.084), myocardial infarction (RR: 0.58; 95% CI: 0.17–1.96; p = 0.379), cardiovascular mortality (RR: 0.68; 95% CI: 0.35–1.34; p = 0.265), hemorrhagic stroke (RR: 0.25; 95% CI: 0.03–2.24; p = 0.217) or all-cause mortality (RR: 0.97; 95% CI: 0.66–1.41; p = 0.857).

Discussion

Anticoagulation in DDAF patients with prior stroke/TIA reduces any stroke recurrence but increases major bleeding risk without raising hemorrhagic stroke incidence. This trade-off underscores the need for individualized risk stratification.

Conclusions

Anticoagulation lowers any stroke recurrence in DDAF patients post-stroke/TIA but raises major bleeding risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationIschemic Attack, TransientStrokeAnticoagulantsHumansRecurrenceSecondary PreventionRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Strokeanticoagulationatrial fibrillationdevice-detected atrial fibrillationprevention

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Second Department of Neurology, "Attikon" University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • Division of Neurology, McMaster University and Population Health Research Institute, Hamilton, ON, Canada.
  • Department of Neurology & Stroke, Eberhard-Karls University of Tuebingen, Tuebingen, Germany.
  • Department of Neurosciences, Bufalini Hospital, AUSL Romagna, Cesena, Italy.
  • Department of Neurology, Universitätsklinikum Essen, Essen, Germany.
  • First Department of Cardiology, National and Kapodistrian University of Athens, School of Medicine, Hippokration Hospital, Athens, Greece.

ORCID-Profile: Lina Palaiodimou, Aristeidis H Katsanos, Konstantinos Melanis, Michele Romoli, Simona Sacco, Georgios Tsivgoulis

Zitieren

APA

Palaiodimou, L., Katsanos, A. H., Melanis, K., Stefanou, M. I., Romoli, M., Papagiannopoulou, G., Theodorou, A., Köhrmann, M., Dilaveris, P., Tsioufis, K., Magiorkinis, G., Krogias, C., Themistocleous, M., Sacco, S., Katan, M., Filippatos, G., & Tsivgoulis, G. (2025). Recurrent stroke in patients with history of stroke/transient ischemic attack and device-detected atrial fibrillation: A systematic review and meta-analysis. European Stroke Journal, 10(4), 1221-1230. https://doi.org/10.1177/23969873251334278

Vancouver

Palaiodimou L, Katsanos AH, Melanis K, Stefanou MI, Romoli M, Papagiannopoulou G, et al. Recurrent stroke in patients with history of stroke/transient ischemic attack and device-detected atrial fibrillation: A systematic review and meta-analysis. European Stroke Journal. 2025;10(4):1221-1230. doi:10.1177/23969873251334278

BibTeX
@article{Palaiodimou2025,
  author = {Palaiodimou, Lina and Katsanos, Aristeidis H and Melanis, Konstantinos and Stefanou, Maria-Ioanna and Romoli, Michele and Papagiannopoulou, Georgia and Theodorou, Aikaterini and Köhrmann, Martin and Dilaveris, Polychronis and Tsioufis, Konstantinos and Magiorkinis, Gkikas and Krogias, Christos and Themistocleous, Marios and Sacco, Simona and Katan, Mira and Filippatos, Gerasimos and Tsivgoulis, Georgios},
  title = {Recurrent stroke in patients with history of stroke/transient ischemic attack and device-detected atrial fibrillation: A systematic review and meta-analysis},
  journal = {European Stroke Journal},
  year = {2025},
  volume = {10},
  number = {4},
  pages = {1221--1230},
  doi = {10.1177/23969873251334278}
}
Kostenlos starten →